Judy R Rees1, Leila A Mott2, Elizabeth L Barry2, John A Baron2,3, Roberd M Bostick4,5, Jane C Figueiredo6,7, Robert S Bresalier8, Douglas J Robertson9,10, Janet L Peacock2,11. 1. Departments of Epidemiology and judith.r.rees@dartmouth.edu. 2. Departments of Epidemiology and. 3. Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC. 4. Department of Epidemiology, Rollins School of Public Health. 5. Winship Cancer Institute, Emory University, Atlanta, GA. 6. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center. 7. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA. 8. Department of Gastroenterology, Hepatology and Nutrition, the University of Texas MD Anderson Cancer Center, Houston, TX. 9. Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH. 10. VA Medical Center, White River Junction, VT; and. 11. Division of Health and Social Care Research, King's College London, London, United Kingdom.
Abstract
BACKGROUND: Many factors have been associated with serum 25-hydroxyvitamin D [25(OH)D] concentrations in observational studies, with variable consistency. However, less information is available on factors affecting the magnitude of changes in serum 25(OH)D resulting from vitamin D supplementation. OBJECTIVE: This study aimed to identify factors associated with the serum 25(OH)D response to supplementation with 1000 IU cholecalciferol/d during the first year of a large, multicenter, randomized, placebo-controlled colorectal adenoma chemoprevention trial. METHODS:Eligible older adults who were not vitamin D-deficient [serum 25(OH)D ≥12 ng/mL] were randomly assigned in a modified 2 × 2 factorial design to 1 of 4 groups: daily 1000 IU cholecalciferol, 1200 mg Ca as carbonate, both, or placebo. Women could elect 2-group (calcium ± cholecalciferol) random assignment. In secondary analyses, we used multivariable models to assess factors associated with serum 25(OH)D concentrations in all enrollees (n = 2753) and with relative changes in serum 25(OH)D after 1 y cholecalciferol supplementation among those randomly assigned (n = 2187). RESULTS: In multivariable models, 8 factors accounted for 50% of the variability of proportional change in serum 25(OH)D after cholecalciferol supplementation. Larger increases were associated with being female (34.5% compared with 20.5%; P < 0.001) and with lower baseline serum 25(OH)D (P < 0.0001), optimal adherence to study pill intake (P = 0.0002), wearing long pants and sleeves during sun exposure (P = 0.0002), moderate activity level (P = 0.01), use of extra vitamin D-containing supplements during the trial (P = 0.03), and seasons of blood draw (P ≤ 0.002). Several genetic polymorphisms were associated with baseline serum 25(OH)D and/or serum response, but these did not substantially increase the models' R2 values. Other factors, including body mass index, were associated with serum 25(OH)D at baseline but not with its response to supplemental cholecalciferol. CONCLUSIONS: The factors that most affected changes in serum 25(OH)D concentrations in response to cholecalciferol supplementation included sex, baseline serum 25(OH)D, supplement intake adherence, skin-covering clothes, physical activity, and season. Genetic factors did not play a major role. This trial was registered at www.clinicaltrials.gov as NCT00153816.
RCT Entities:
BACKGROUND: Many factors have been associated with serum 25-hydroxyvitamin D [25(OH)D] concentrations in observational studies, with variable consistency. However, less information is available on factors affecting the magnitude of changes in serum 25(OH)D resulting from vitamin D supplementation. OBJECTIVE: This study aimed to identify factors associated with the serum 25(OH)D response to supplementation with 1000 IU cholecalciferol/d during the first year of a large, multicenter, randomized, placebo-controlled colorectal adenoma chemoprevention trial. METHODS: Eligible older adults who were not vitamin D-deficient [serum 25(OH)D ≥12 ng/mL] were randomly assigned in a modified 2 × 2 factorial design to 1 of 4 groups: daily 1000 IU cholecalciferol, 1200 mg Ca as carbonate, both, or placebo. Women could elect 2-group (calcium ± cholecalciferol) random assignment. In secondary analyses, we used multivariable models to assess factors associated with serum 25(OH)D concentrations in all enrollees (n = 2753) and with relative changes in serum 25(OH)D after 1 y cholecalciferol supplementation among those randomly assigned (n = 2187). RESULTS: In multivariable models, 8 factors accounted for 50% of the variability of proportional change in serum 25(OH)D after cholecalciferol supplementation. Larger increases were associated with being female (34.5% compared with 20.5%; P < 0.001) and with lower baseline serum 25(OH)D (P < 0.0001), optimal adherence to study pill intake (P = 0.0002), wearing long pants and sleeves during sun exposure (P = 0.0002), moderate activity level (P = 0.01), use of extra vitamin D-containing supplements during the trial (P = 0.03), and seasons of blood draw (P ≤ 0.002). Several genetic polymorphisms were associated with baseline serum 25(OH)D and/or serum response, but these did not substantially increase the models' R2 values. Other factors, including body mass index, were associated with serum 25(OH)D at baseline but not with its response to supplemental cholecalciferol. CONCLUSIONS: The factors that most affected changes in serum 25(OH)D concentrations in response to cholecalciferol supplementation included sex, baseline serum 25(OH)D, supplement intake adherence, skin-covering clothes, physical activity, and season. Genetic factors did not play a major role. This trial was registered at www.clinicaltrials.gov as NCT00153816.
Authors: John A Baron; Elizabeth L Barry; Leila A Mott; Judy R Rees; Robert S Sandler; Dale C Snover; Roberd M Bostick; Anastasia Ivanova; Bernard F Cole; Dennis J Ahnen; Gerald J Beck; Robert S Bresalier; Carol A Burke; Timothy R Church; Marcia Cruz-Correa; Jane C Figueiredo; Michael Goodman; Adam S Kim; Douglas J Robertson; Richard Rothstein; Aasma Shaukat; March E Seabrook; Robert W Summers Journal: N Engl J Med Date: 2015-10-15 Impact factor: 91.245
Authors: K Brock; W-Y Huang; D R Fraser; L Ke; M Tseng; R Stolzenberg-Solomon; U Peters; J Ahn; M Purdue; R S Mason; C McCarty; R G Ziegler; B Graubard Journal: J Steroid Biochem Mol Biol Date: 2010-04-22 Impact factor: 4.292
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: Shanna Nesby-O'Dell; Kelley S Scanlon; Mary E Cogswell; Cathleen Gillespie; Bruce W Hollis; Anne C Looker; Chris Allen; Cindy Doughertly; Elaine W Gunter; Barbara A Bowman Journal: Am J Clin Nutr Date: 2002-07 Impact factor: 7.045
Authors: Anne C Looker; Christine M Pfeiffer; David A Lacher; Rosemary L Schleicher; Mary Frances Picciano; Elizabeth A Yetley Journal: Am J Clin Nutr Date: 2008-12 Impact factor: 7.045
Authors: Corinne D Engelman; Kristin J Meyers; Sudha K Iyengar; Zhe Liu; Chitra K Karki; Robert P Igo; Barbara Truitt; Jennifer Robinson; Gloria E Sarto; Robert Wallace; Barbara A Blodi; Michael L Klein; Lesley Tinker; Erin S LeBlanc; Rebecca D Jackson; Yiqing Song; JoAnn E Manson; Julie A Mares; Amy E Millen Journal: J Nutr Date: 2012-11-28 Impact factor: 4.798
Authors: Serwet Demirdas; Francjan J van Spronsen; Carla E M Hollak; J Hanneke van der Lee; Peter H Bisschop; Fred M Vaz; Nienke M Ter Horst; M Estela Rubio-Gozalbo; Annet M Bosch Journal: Ann Nutr Metab Date: 2017-03-24 Impact factor: 3.374
Authors: Buthaina E Alathari; David A Nyakotey; Abdul-Malik Bawah; Julie A Lovegrove; Reginald A Annan; Basma Ellahi; Karani S Vimaleswaran Journal: Nutrients Date: 2022-07-04 Impact factor: 6.706
Authors: Maria G Grammatikopoulou; Konstantinos Gkiouras; Meletios P Nigdelis; Dimitrios P Bogdanos; Dimitrios G Goulis Journal: Nutrients Date: 2020-03-04 Impact factor: 5.717